Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 93Stomach Neoplasms 56Rectal Neoplasms 51Colonic Neoplasms 47Pancreatic Neoplasms 20Neoplasms 14Carcinoma, Hepatocellular 14Neoplasm Metastasis 13Adenocarcinoma 10Parkinson Disease 4, Autosomal Dominant Lewy Body 9Lymphoma, Large B-Cell, Diffuse 9Cholangiocarcinoma 8Adenocarcinoma Of Esophagus 8Esophageal Neoplasms 5Biliary Tract Neoplasms 5Neurotoxicity Syndromes 4Esophageal Squamous Cell Carcinoma 4Lymphoma, Extranodal NK-T-Cell 3Gastrointestinal Neoplasms 3Gallbladder Neoplasms 3Peritoneal Neoplasms 2Lymphoma 2Liver Neoplasms 2Hepatoblastoma 2Gastrointestinal Diseases 2Colorectal Adenocarcinoma 2Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Spinocerebellar Degenerations 1

Interventions

Paclitaxel 45Carboplatin 33Bevacizumab 17liposomal doxorubicin 15Topotecan 12Taxes 10Gemcitabine 10Drug Therapy 6Cisplatin 6rucaparib 5mirvetuximab soravtansine 5Docetaxel 5Immunoglobulin G 4Doxorubicin 4Disulfides 4trebananib 3pembrolizumab 3olaparib 3Saline Solution 3Neoadjuvant Therapy 3Hyperthermic Intraperitoneal Chemotherapy 3Dexamethasone 3CP protocol 3niraparib 2cediranib 2Tamoxifen 2Specimen Handling 2Letrozole 2Glucose 2Cytoreduction Surgical Procedures 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Fallopian Tube Neoplasms × Oxaliplatin × Clear all
NCT01081262 2026-04-30

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
50 enrolled 13 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡